This Week in Oncology — May 28, 2026

Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning new therapeutic strategies in solid tumors, innovations in cell therapy, and fundamental mechanisms of cancer biology. We'll also flag two key guideline updates from ASCO. Let's dive in.
This week's papers:
• Human haematopoietic stem cells remember inflammatory stress. — Nature 2026 (pubmed.ncbi.nlm.nih.gov/42203882)
• Farnesylation-driven KRAS phase separation promotes colon tumor growth. — Cell 2026 (pubmed.ncbi.nlm.nih.gov/42202789)
• Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. — The New England journal of medicine 2026 (pubmed.ncbi.nlm.nih.gov/42202319)
• Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. — Science translational medicine 2026 (pubmed.ncbi.nlm.nih.gov/42202046)
• Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial. — Nature medicine 2026 (pubmed.ncbi.nlm.nih.gov/42191879)
• Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1. — Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42190141)
• Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. — Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42190141)
• Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases. — Nature cancer 2026 (pubmed.ncbi.nlm.nih.gov/42174275)
Listen at AudioScholar (audioscholar.cc/episode/qmkkxfeqsp)